ASTCT (@ASTCT) header
ASTCT (@ASTCT) profile picture

The American Society for Transplantation and Cellular Therapy Scientific Journal: @ASTCT_Journal #Tandem27

Chicago, Illinois
Joined April 2013
Be part of the conversations shaping the future of transplantation and cellular therapy at #Tandem27. Join leading clinicians, researchers and health care professionals for practice-changing science, collaborative learning and unparalleled networking opportunities. Explore the latest advances in #HCT, #CellularTherapy and #GeneTherapy while connecting with experts from around the world. Register: tandemmeetings.org
2
194
New on ASTCT Nucleus: Could a subset of glioblastomas be better suited for immunotherapy than previously thought? Researchers identified clonally expanded, exhausted CD8⁺ tumor-infiltrating lymphocytes (TILs) in a small but distinct group of TIL-rich glioblastomas, suggesting the presence of tumor-reactive immune responses. The findings support further exploration of antigen-specific immunotherapies and LAG-3–targeted approaches in patients whose tumors harbor these immune-active characteristics. Read more: ow.ly/jz2M5105V2w
1
3
351
Have a story to tell? ASTCT Nucleus is now accepting submissions for its new Narrative Medicine series, featuring reflections from patients, caregivers, clinicians, researchers, and trainees that explore the human side of transplantation and cellular therapy. Read the inaugural article, Beyond the Blood Counts, and submit your own story: ow.ly/Ry1f5105V0B
2
5
343
Why pay full price for #Tandem27? Register before Nov. 20 to access the best rates for your full team. Register today: ow.ly/RNon5105aWp
2
394
ASTCT Abstract Travel Grants are granted to qualified, in-training or junior faculty ASTCT members who are listed as authors on abstracts accepted for the Tandem Meetings. 30 grants of $1,500 each will be awarded to selected grantees. Learn more and apply: ow.ly/iWx65105UVM
2
6
595
New on ASTCT Nucleus: Can off-the-shelf regulatory T-cell (Treg) therapy help prevent graft-versus-host disease (GVHD)? Results from a first-in-human trial showed that gp120-activated allogeneic Tregs (ATreg) derived from HLA-unmatched donors were safely administered after allogeneic hematopoietic cell transplantation, with no infusion-related toxicities and no cases of grade 3-4 acute GVHD within the first 100 days after transplant. The findings support further investigation of this novel, rapidly manufactured cell therapy approach for GVHD prevention. Read more: ow.ly/VeSt5105UZ4
3
2
499
Which patients with AML or MDS are appropriate candidates for reduced-toxicity conditioning before allo-HCT? As transplant eligibility expands to older adults and patients with comorbidities, conditioning decisions require careful consideration of factors beyond chronological age. Explore expert-led education on patient selection and learn how factors such as comorbidity burden, performance status, disease risk, and MRD status can inform individualized conditioning decisions. #AML #MDS #StemCellTransplant #Hematology #MedicalEducation #AlloHCT Access the program: ow.ly/qZ0W50ZPMUl
1
5
411
New on ASTCT Nucleus: Could malignant pleural effusions (MPEs) provide a less invasive source of cells for tumor-infiltrating lymphocyte (TIL) therapy? Researchers found that pleural fluid collected through thoracentesis contained many of the same tumor-reactive T-cell clones found in tumor tissue, but with lower levels of exhaustion and strong expansion potential. The findings support MPE as a promising alternative starting material for TIL manufacturing in patients with advanced cancer. Read more: ow.ly/1fpz5105UUh
2
3
416
#Tandem27 Session Spotlight: Four investigators will share how they use CIBMTR and its datasets to build professional networks, mentorship opportunities, support graduate education and impact clinical practice. Learn more and register: ow.ly/SuMu5105UTV #ASTCT #Tandem27
1
4
472
Can CD123-directed CAR T-cell therapy safely target relapsed or refractory acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)? Results from a phase I trial suggest that CD123-targeted CAR T cells can be administered without the prolonged myeloablation predicted by earlier preclinical studies. While remissions were limited and often short-lived, the findings provide important insights into the safety, feasibility, and future development of CAR T-cell therapy for myeloid malignancies. Read more: ow.ly/3uiw5105URK
1
4
18
1,513
The ASTCT SIG Travel Grant program awards grants to selected members of the following Special Interest Groups (SIGs) to allay the costs of attending the 2027 Tandem Meetings: •Advanced Practice Professional •Nursing •Pharmacy Deadline Dec 12. Learn more and apply: ow.ly/xJ2o5105UNH
1
3
440
Join the ASTCT Pharmacy SIG on Nov. 18 for a Journal Club discussion of recent literature impacting transplantation and cellular therapy pharmacy practice. Madeleine Hosick, PharmD, of Duke University Hospital, and Olivia Robida, PharmD, of The Ohio State University Wexner Medical Center will review key findings from the featured publication and discuss their implications for clinical practice and patient care. Register: learn.astct.org/products/ast…
1
4
407
Can less antibiotic exposure lead to better outcomes after transplant? In this ASTCT Talks podcast episode, Diego R. Hijano, MD, MSc, Gabriela Marón, MD, MSc, and Fareed Khawaja, MBBS, discuss emerging data on antibiotic de-escalation, microbiome preservation, antimicrobial resistance, and evolving approaches to infection management in hematopoietic cell transplantation. Tune in: ow.ly/JATU5105UIw
3
5
426
How are emerging HSC manipulation strategies transforming transplantation and gene therapy? Join John DiPersio, MD, PhD and Hans-Peter Kiem, MD, PhD for this #Tandem27 session exploring innovative approaches, clinical applications and the latest research advances. Register: ow.ly/PYMN5105bGa
2
438
Coming up this week: ASTCT's Pharmacy Journal Club webinar. Join Drs. Hosick and Robida on Nov. 18 for discussion and analysis of current literature impacting pharmacy in transplantation and cellular therapy. Register: ow.ly/y3RU5105bxZ
1
462
#Tandem27 Grant Opportunity: The Jeff Gordon Children's Foundation Travel Grants will provide travel grants to 10 young investigators who meet the following criteria: ✅ Is a medical resident, fellow, or within five years of their initial faculty appointment ✅ Is attending the 2027 Tandem Meetings in person ✅ Treats or conducts research in pediatric populations ✅ Has not been previously awarded Award open to U.S. and international applicants; deadline Nov. 9. 🔗ow.ly/SOGb5105bsK
4
459
Should fitness for CAR T-cell therapy and transplantation be defined differently? In their latest thought leadership article on Nucleus, Marco Ruiz, MD, and Marc J. Braunstein, MD, PhD, FACP, FASCO, argue for treatment-specific, multidimensional approaches to frailty assessment that move beyond age, performance status, and comorbidity scores alone Read the article: ow.ly/IMJv5105bg1
1
2
441
Presenting your research at #Tandem27? Check out the Tandem Abstract Travel Grant opportunity and see if you qualify for funding. You can apply for a travel grand ahead of abstract notifications for the meetings Apply by Dec. 14: ow.ly/stUz5105bc0
1
4
431
The Call for Volunteers closes today. Help shape Society programs and initiatives while building meaningful connections across the field. Submit your interest before the deadline: astct.org/Membership/Volunte…
1
408
ASTCT is still accepting volunteer applications for multiple committees making an impact across the Society. The Call for Volunteers closes tomorrow on Nov. 13. Learn more and submit your interest: ow.ly/4w9z5105aI4
1
473